Skip to main content

Articles

ASH 2018 - Chronic Lymphocytic Leukemia
MURANO Study: The Impact of Minimal Residual Disease on Long-Term Clinical Outcomes After Venetoclax plus Rituximab
Read More
ASH 2018 - Chronic Lymphocytic Leukemia
CLL Treatment Patterns, Dosing, and Sequencing: Interim Analysis Results from the Prospective informCLL Real-World Registry
Read More
ASH 2018 - Chronic Lymphocytic Leukemia
The Combination of Ibrutinib with Anti-CD19 CAR T-Cells Shows a High Response Rate in the Treatment of CLL
Read More
Original Research, Practice Management
Computed Tomography Colonography Less Costly Than Colonoscopy for Colorectal Cancer Screening of Commercially Insured Patients
Tia Goss Sawhney, DrPH, FSA, MAAA; Bruce S. Pyenson, FSA, MAAA; David Rotter, PhD; Michele Berrios; Judy Yee, MD
Read More
Original Research, Practice Management
Alternative Payment Models in Medical Oncology: Assessing Quality-of-Care Outcomes Under Partial Capitation
Derek Ems, MPH; Sharanya Murty, PhD; Bryan Loy, MD; Judith Gallagher, MBA; Laura E. Happe, PharmD, MPH; Teresa L. Rogstad, MPH; Debra Finnel; Jimmy D. Fernandez, MD, MBA
Read More
Original Research, Practice Management
Budget Impact Analysis of Using Daunorubicin-Cytarabine Liposome in Patients with Newly Diagnosed Therapy-Related AML or AML and Myelodysplasia-Related Changes
Ivar S. Jensen, MBA; Elizabeth Wu, MPH; Naomi C. Sacks, PhD; Philip L. Cyr, MPH; Karen C. Chung, PharmD, MS
Read More
Perspectives
“Hoodoo” You Think Will Change?
David B. Nash, MD, MBA
Read More
Original Research, Practice Management
Economic Burden of Adverse Events Associated with Immunotherapy and Targeted Therapy for Metastatic Melanoma in the Elderly
Sameer R. Ghate, PhD; Zhiyi Li, MBA, MA; Jackson Tang, MSc; Antonio Reis Nakasato, MD
Stakeholder Perspective
It’s About the Total Cost of Care
Gary M. Owens, MD
Read More
Pain
Analysis of Real-World Dosing Patterns for the 3 FDA-Approved Medications in the Treatment of Fibromyalgia
Craig White, PhD; Winghan Jacqueline Kwong, PharmD, PhD; Hilary Armstrong, PhD; Michael Behling; Jeffrey Niemira; Kathy Lang, PhD
Stakeholder Perspective
Real-World Drug Prescribing and Utilization Studies Can Inform Optimized Patient Care and Insurance Coverage
F. Randy Vogenberg, PhD, RPh
Read More
Perspectives
"The Dirty Dozen"
David B. Nash, MD, MBA
Read More
Page 64 of 244
Results 631 - 640 of 2434